drugset / Trial / NCT00372723

Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)

NCT00372723

Phase 2 Withdrawn Loyola University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.

Timeline

Start
2006-07
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 5 mg/kg Intravenous